Houvras Yariv reported grant involving 105,000 derivative units of Xilio Therapeutics, Inc. at $0.00 for $0 on Oct 1, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
CHIEF MEDICAL OFFICER
CHIEF MEDICAL OFFICER
Filed Oct 2, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
105,000Stock Option (right to buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
105,000Direct
Trade date
Oct 1, 2026Grant
Filed
Oct 2, 2026, 4:33 PM ET1-day reporting delay
Accession
0001193125-26-412466Code A · Transaction 234951
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

XLO price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
XLO · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −1.4%1w ago −0.1%1d ago +0.4%
Returns since7d +0.4%30d −11%90d180d1y

Footnotes in full

F1: The option was granted on October 1, 2026 and will vest with respect to 25% of the shares of common stock underlying the stock option on September 28, 2027, and the remaining 75% of the shares of common stock underlying the stock option will continue to vest in 36 equal monthly installments thereafter.